ScreenerHero

GRCE Grace Therapeutics, Inc.

NAS · US · Healthcare · Biotechnology · gracetx.com
2.100USD+1.69%Mkt Cap: 44.18M $P/E: —

Grace Therapeutics, Inc. engages in the development and commercialization of pharmaceutical products for rare and orphan diseases in Canada. The company's lead product candidate is the GTX-104, an injectable formulation …

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$128.08BUSDP/E 29.4
MRNA
Moderna, Inc.
$78.44BUSD
REGN
Regeneron Pharmaceuticals, Inc.
$76.40BUSDP/E 18.4
ARGX
argenx SE
$57.03BUSDP/E 37.3
ARGX
argenx SE
$58.08BUSDP/E 35.4
UCB
UCB SA
$42.24BUSDP/E 18.0
RVMD
Revolution Medicines, Inc.
$43.05BUSD
ONC
BeOne Medicines AG
$41.41BUSDP/E 65.1
RPRX
Royalty Pharma plc
$32.80BUSDP/E 30.2
ALNY
Alnylam Pharmaceuticals, Inc.
$30.03BUSDP/E 37.8
ROIV
Roivant Sciences Ltd.
$25.10BUSD
BNTX
BioNTech SE
$23.93BUSD
INCY
Incyte Corporation
$22.99BUSDP/E 14.5
GMAB
Genmab A/S
$22.27BUSDP/E 30.7
GMAB
Genmab A/S
$22.54BUSDP/E 28.9
INSM
Insmed Incorporated
$22.22BUSD
ASND
Ascendis Pharma A/S
$15.03BUSDP/E 17.5
JAZZ
Jazz Pharmaceuticals plc
$15.01BUSDP/E 15.8
EXEL
Exelixis, Inc.
$14.48BUSDP/E 18.4
SMMT
Summit Therapeutics Inc.
$14.32BUSD

Key Statistics

Company
Market Cap44.18M USD
Enterprise Value29.68M USD
Revenue (TTM)—
Gross Profit—
Net Income (TTM)-7.79M USD
Revenue/Share—
Last Price2.100 USD
Fiscal Year EndMar 2026
MR QuarterJun 2026
Employees5
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-4.60
PEG—
EV/EBITDA-2.86
EV/Revenue—
P/S—
P/B0.70
EPS (TTM)-1.17
EPS (Forward)-0.45
52W Range
1.7909% of range5.180
52W High5.180 USD
52W Low1.790 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-12.20%
ROA-11.69%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-8.87M USD
CapEx (TTM)—
FCF Margin—
FCF Yield-15.84%
Net Debt-13.76M USD
Net Debt/EBITDA1.33
Balance Sheet
Debt/Equity—
Current Ratio11.47
Quick Ratio11.02
Book Value/Sh2.96 USD
Cash/Share0.65 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Splits
Last Split1:6
Split DateJul 10, 2023
Analyst Consensus
Rating—
Target (Mean)5.864 USD
Upside (mean)+179.3%
Target Range3.900 USD – 7.828 USD
3.900+179.3% to mean7.828
# Analysts2
Ownership
Shares Out.21.04M
Float13.53M
Insiders18.68%
Institutions31.51%
Short Interest
Short Ratio12.2d
Short % Float9.69%
Short % Out.8.39%
Shares Short1.77M
Short (prev mo.)1.62M
Technical
SMA 502.141 (-1.9%)
SMA 2002.966 (-29.2%)
Beta0.33
S&P 52W Chg16.45%
Avg Vol (30d)136.61K
Avg Vol (10d)118.37K
Technical Indicators
RSI (14)46.9
MACD-0.0270
MACD Signal-0.0225
MACD Hist.-0.0045
BB Upper2.270 USD
BB Middle2.136 USD
BB Lower2.002 USD
BB Width12.53%
ATR (14)0.0928 USD
Vol Ratio (20d)0.52x